Physician profile
Kyle Branson
NPI 1376169433
$3,503.82
in general payments reported to CMS, 2019-2025
28 companies · $983 in 2025
The $983 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.56 · 2022: $1,352 · 2023: $476 · 2024: $648 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,106.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elite Orthopedics, LLC | $1,200.00 | 2022 | |
| Abbvie INC. | $374.63 | 2023-2025 | Ubrelvy |
| Lilly USA, LLC | $300.60 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $252.09 | 2021-2025 | Breztri, Airsupra, Saphnelo |
| Pfizer INC. | $235.17 | 2023-2025 | |
| Novo Nordisk INC | $200.50 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Medicure Pharma INC. | $104.73 | 2023 | Zypitamag |
| Amgen INC. | $98.56 | 2021-2025 | Repatha, Otezla, Repatha |
| Esperion Therapeutics, INC. | $97.72 | 2024-2025 | Nexletol, Nexlizet |
| Glaxosmithkline, LLC. | $81.96 | 2023-2025 | Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $77.96 | 2024-2025 | Gemtesa |
| Daiichi Sankyo INC. | $59.25 | 2023-2024 | Injectafer |
| Ucb, INC. | $47.84 | 2024-2025 | Cimzia, Bimzelx |
| Janssen Pharmaceuticals, INC | $47.71 | 2022-2024 | Xarelto |
| Exact Sciences Corporation | $43.30 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $34.70 | 2025 | |
| Janssen Biotech, INC. | $27.48 | 2025 | Tremfya |
| Philips North America LLC | $27.28 | 2024 | (8874) Incourage |
| Medtronic, INC. | $22.72 | 2025 | Inceptiv |
| E.R. Squibb & Sons, L.L.C. | $22.24 | 2025 | Eliquis |
| Lundbeck LLC | $21.72 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $19.43 | 2023 | |
| Kaleo, INC. | $19.42 | 2022 | |
| Abbott Laboratories | $18.95 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $18.43 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.28 | 2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.24 | 2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $14.91 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Branson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.